ATNM Actinium Corp Earnings per share growth rate in current year

Official company branding of actiniumpharma.com (ATNM)

Actinium Pharmaceuticals (ATNM) is growing its capital through partnerships with pharma behemoths to bring radioimmunotherapy to market. Annual EPS growth demonstrates profit dynamics, where 122.10 indicates the current level. However, geopolitical risks are undermining drug logistics, and an excessive bet on final trials creates a dependency on a single regulatory decision.

ATNM - Actinium Pharmaceuticals, Inc. Earnings growth in current year over the range 07/04/2022 - 11/18/2026

Comprehensive metric breakdowns and analytics for Actinium Pharmaceuticals (ATNM)

- stock value and consensus price forecast:
Fundamental valuation:ATNM - Actinium Corp
Core merchandise of Actinium Corp

Actinium Pharmaceuticals operates in the high-risk radiopharmaceutical sector. The year-over-year (YoY) net income per share change ratio reflects EPS dynamics relative to the same period last year. Growth in this metric signals the effective capitalization of scientific research. For Actinium Pharmaceuticals (ATNM), such a metric confirms financial stability while adhering to strict bioethical and radiation ESG standards. A positive trend justifies the company's investment attractiveness.